Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. 1987

S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
Dipartimento di Medicina Interna e Terapia Medica, Università di Pavia, Italy.

A specific hemorheologic treatment might reduce urinary protein excretion and the decline in kidney function in diabetic patients with overt clinical nephropathy. Twenty-one insulin dependent (type I) diabetic patients were randomized and assigned to a treatment with conventional antihypertensive therapy (protocol I) or with pentoxifylline (Trental 400) (protocol II). A marked improvement of blood rheology pattern, together with a reduction of urinary albumin excretion rate and total urinary protein excretion rate, was demonstrated throughout a 1-year follow-up study with pentoxifylline. Furthermore a decrease of systolic and diastolic blood pressure levels was found during the treatment. The modification of these parameters was followed by a significant increase of creatinine clearance in each of the patients studied. The results obtained during pentoxifylline therapy were comparable to those obtained in patients treated with conventional antihypertensive drugs. Pentoxifylline may therefore be used in the treatment of advanced nephropathy in diabetic patients.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010431 Pentoxifylline A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. Agapurin,BL-191,Oxpentifylline,Pentoxil,Torental,Trental,BL 191,BL191
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D003000 Clonidine An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. Catapres,Catapresan,Catapressan,Chlophazolin,Clofelin,Clofenil,Clonidine Dihydrochloride,Clonidine Hydrochloride,Clonidine Monohydrobromide,Clonidine Monohydrochloride,Clopheline,Dixarit,Gemiton,Hemiton,Isoglaucon,Klofelin,Klofenil,M-5041T,ST-155,Dihydrochloride, Clonidine,Hydrochloride, Clonidine,M 5041T,M5041T,Monohydrobromide, Clonidine,Monohydrochloride, Clonidine,ST 155,ST155
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson

Related Publications

S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
April 1986, Diabetologia,
S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
August 1999, Nihon Jinzo Gakkai shi,
S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
March 2004, Biochemical and biophysical research communications,
S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
June 1995, European journal of endocrinology,
S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
December 1985, Irish journal of medical science,
S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
April 1981, Diabetologia,
S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
January 1992, Acta diabetologica,
S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
August 2005, Diabetes care,
S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
January 1987, Diabetic medicine : a journal of the British Diabetic Association,
S B Solerte, and M Fioravanti, and A L Patti, and N Schifino, and M G Zanoletti, and V Inglese, and E Ferrari
January 1993, Diabetes research and clinical practice,
Copied contents to your clipboard!